Relay Therapeutics, Inc. — Director's Dealing 2021

Apr 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Relay Therapeutics, Inc. (RLAY)
CIK: 0001812364
Period of Report: 2021-03-30

Reporting Person: Catinazzo Thomas (Senior Vice President, Finance)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-30	Common Stock	M	22500	$4.12	Acquired	22500	Direct
2021-03-30	Common Stock	S	22500	$35.00	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-30	Stock Option (Right to Buy)	$4.12	M	22500	Disposed	2028-04-09	Common Stock (22500)	Direct

Footnotes

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2020.

F2: Twenty-five percent (25%) of the shares underlying this option vested on April 9, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.